Evidence map›Paper›PMID 41409290›Full record

ArticleFrontiers in immunology2025

SDCBP2 promotes tumor progression and is a novel ferroptosis-related prognostic biomarker in lung adenocarcinoma.

Shaowu Sun, Zhuoyu Gu, Shuang Yuan, Kaishang Zhang, Wei Liu, Zhengpan Wei, Wenbo Fan, Zelong Wang, Tianliang Zhao, Mingbo Tang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shaowu Sun *State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Zhuoyu Gu *Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Shuang Yuan *Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Kaishang ZhangDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Wei LiuDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Zhengpan WeiDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Wenbo FanDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Zelong WangDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Tianliang ZhaoDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Mingbo TangDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Xinliang GaoDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.
Guoqing ZhangDepartment of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Xiangnan LiState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Xue PanState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lung adenocarcinoma (LUAD) is a global health threat due to its rapid malignant progression and poor prognosis. Ferroptosis plays a key role in LAUD progression, but the critical ferroptosis-related factors in LUAD have not been further explored. The aim of this work was to explore novel ferroptosis-related therapeutic targets and prognostic biomarkers for LUAD. Methods: Using TCGA and GEO datasets of LAUD samples, we constructed a ferroptosis risk model and identified SDCBP2 as a LUAD hub gene. The TCGA data and single-cell database indicated that SDCBP2 was overexpressed in LUAD and significantly enriched in malignant cells. Subsequently, bioinformatics analysis, functional studies, and clinical samples were employed to assess the prognostic value and role of SDCBP2. Results: The multivariate Cox regression confirmed SDCBP2 as an independent prognostic factor. The ROC curve based on SDCBP2 expression showed a strong predictive power for the prognosis of LUAD patients at 1, 3, and 5 years. The GSEA and GO/KEGG analysis linked SDCBP2 to ferroptosis and cell cycle pathways. Next, the Discussion: This study demonstrates that SDCBP2 promotes tumor progression and is a novel ferroptosis-related prognostic biomarker for LUAD.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorFerroptosisLung NeoplasmsCell Line, TumorCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, Tumorapoptosiscell cycleferroptosislung adenocarcinomaprognostic markerSDCBP2

Identifiers

PMID41409290
PMCPMC12705533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.